Virax Biolabs Group Limited
$0.14
▼
-12.96%
2026-04-21 10:09:01
viraxbiolabs.com
NCM: VRAX
Explore Virax Biolabs Group Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.05 M
Current Price
$0.14
52W High / Low
$1.2 / $0.1
Stock P/E
—
Book Value
$0.81
Dividend Yield
—
ROCE
-107.11%
ROE
-83.82%
Face Value
—
EPS
$-1.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
1.6
Debt / Equity
10.6
Current Ratio
11.35
Quick Ratio
7.13
Forward P/E
-0.43
Price / Sales
258.8
Enterprise Value
$-2.46 M
EV / EBITDA
0.44
EV / Revenue
-822.89
Rating
None
Target Price
$1
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 2. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
| 3. | Serina Therapeutics, Inc. | $2.1 | — | $25.86 M | — | -709.03% | -81.59% | $7.92 / $1.22 | $-0.46 |
| 4. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 5. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 6. | Bio-Techne Corporation | $59.22 | 116.91 | $9.33 B | 0.53% | 10.19% | 3.97% | $72.16 / $46.01 | $12.9 |
| 7. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.01 M | 0.16 M | 0.01 M | 0 M |
| Operating Profit | -6.16 M | -6.11 M | -5.73 M | -1.73 M |
| Net Profit | -6.06 M | -6.73 M | -5.46 M | -1.71 M |
| EPS in Rs | -0.82 | -0.91 | -0.74 | -0.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.43 M | 5.48 M | 9.81 M | 0.05 M |
| Total Liabilities | 0.96 M | 0.35 M | 0.91 M | 1.25 M |
| Equity | 5.7 M | 5.37 M | 9.13 M | -0.97 M |
| Current Assets | 4.89 M | 4.38 M | 9.63 M | 0.05 M |
| Current Liabilities | 0.67 M | 0.17 M | 0.91 M | 1.25 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.56 M | -6.25 M | -4.18 M | -0.81 M |
| Investing CF | -0.6 M | -1.16 M | -0.18 M | 0 M |
| Financing CF | 5.81 M | 1.65 M | 13.69 M | 0.81 M |
| Free CF | -5.17 M | -7.41 M | -4.36 M | -0.81 M |
| Capex | -0.6 M | -1.16 M | -0.18 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -95.95% | 1727.11% | — | — |
| Earnings Growth % | 9.98% | -23.38% | -219.37% | — |
| Profit Margin % | -95739.17% | -4304.81% | -63748.32% | — |
| Operating Margin % | -97344.76% | -3903.69% | -66963.68% | — |
| Gross Margin % | -838.21% | 32.34% | -15.94% | — |
| EBITDA Margin % | -91649.46% | -4225.28% | -63570.79% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-12-18 | 1:0.1 |